Citadel Advisors
TSHA icon

Citadel Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Citadel Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.84M Sell
411,135
-1,443,720
-78% -$6.71M ﹤0.01% 6255
2025
Q4 		$10.2M Buy
1,854,855
+1,487,546
+405% +$7.22M ﹤0.01% 3235
2025
Q3 		$1.2M Sell
367,309
-161,684
-31% -$458K ﹤0.01% 7144
2025
Q2 		$1.22M Buy
528,993
+312,382
+144% +$679K ﹤0.01% 6660
2025
Q1 		$301K Sell
216,611
-528,594
-71% -$884K ﹤0.01% 9580
2024
Q4 		$1.29M Sell
745,205
-2,114,767
-74% -$4.39M ﹤0.01% 6519
2024
Q3 		$5.75M Buy
2,859,972
+2,813,118
+6,004% +$6.17M ﹤0.01% 3736
2024
Q2 		$105K Buy
46,854
+46,657
+23,684% +$136K ﹤0.01% 10845
2024
Q1 		$566 Sell
197
-2,297,359
-100% -$4.79M ﹤0.01% 14308
2023
Q4 		$4.07M Buy
+2,297,556
New +$4.58M ﹤0.01% 4099
2023
Q3 		– Sell
-11,293
Closed -$21.1K – 15133
2023
Q2 		$7.46K Hold
11,293
– – ﹤0.01% 13371
2023
Q1 		$9.01K Sell
11,293
-172,418
-94% -$223K ﹤0.01% 13613
2022
Q4 		$415K Buy
183,711
+133,131
+263% +$270K ﹤0.01% 8628
2022
Q3 		$97K Sell
50,580
-60,011
-54% -$218K ﹤0.01% 11123
2022
Q2 		$411K Sell
110,591
-98,158
-47% -$389K ﹤0.01% 9092
2022
Q1 		$1.36M Buy
208,749
+172,412
+474% +$1.29M ﹤0.01% 6950
2021
Q4 		$423K Buy
+36,337
New +$548K ﹤0.01% 10075
2021
Q1 		– Sell
-35,752
Closed -$949K – 13725
2020
Q4 		$949K Sell
35,752
-209,282
-85% -$4.51M ﹤0.01% 6904
2020
Q3 		$5.49M Buy
+245,034
New +$5.76M ﹤0.01% 3015

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's TSHA Position: Q1 2026 in Review

Citadel Advisors reduced its Taysha Gene Therapies (TSHA) stake by 78% in Q1 2026, selling an estimated $6.71M and leaving 411,135 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #6255.

Citadel Advisors first reported a position in TSHA in Q3 2020 and has held it in 19 quarters since. The position peaked at $10.2M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Citadel Advisors held 411,135 shares of Taysha Gene Therapies worth $1.84M as of Q1 2026.
  • Citadel Advisors sold 1,443,720 Taysha Gene Therapies shares in Q1 2026, an estimated $6.71M.
  • Taysha Gene Therapies made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6255 holding.
  • Citadel Advisors first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 19 quarters since.
  • Citadel Advisors's Taysha Gene Therapies position peaked at $10.2M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.